Phage therapy program
Eligo Bioscience
| Status | Research/development |
|---|---|
| Type | Company |
| Location | Paris; France |
| Entry review | 2026-10-03 |
Access and enquiries
| How to enquire | Corporate/research inquiry; no current patient intake route established. |
|---|---|
| Areas of work | Microbiome gene editing and genetic-circuit delivery using phage-derived particles, including antibacterial CRISPR approaches. |
| International access | No established international patient access route. |
What to confirm
- Phage-derived delivery technology is not equivalent to a general natural-lytic-phage clinic.
- A first human trial start was not established in this pass.
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Program ID | eu-eligo |
|---|